Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
26.54
+0.47 (+1.80%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 01, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 18, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
November 17, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
November 17, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
November 05, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
6 Analysts Have This To Say About Stoke Therapeutics
↗
November 05, 2025
Via
Benzinga
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Where Stoke Therapeutics Stands With Analysts
↗
August 13, 2025
Via
Benzinga
A Look Ahead: Stoke Therapeutics's Earnings Forecast
↗
August 11, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 04, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Examining the Future: Stoke Therapeutics's Earnings Outlook
↗
November 03, 2025
Via
Benzinga
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
October 30, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
October 20, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 16, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Stoke Therapeutics
↗
October 10, 2025
Via
Benzinga
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
October 09, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
October 09, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
October 06, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 16, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 02, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 02, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025
August 28, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
August 25, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
August 25, 2025
From
Biogen Inc.
Via
GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 18, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 11, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 11, 2025
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
